There are currently 2864 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938
Recruiting
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Community-acquired Pneumonia
Register for Updates
Harmony & Health: Feasibility of a Movement Intervention to Improve Psychosocial Wellbeing in Black Adults in Northeast Texas
NCT05761964
Recruiting
To test the feasibility and acceptability of a program that combines yoga practices and Christian spirituality (called Harmony \& Health) amongst insufficiently active Black adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Psychological
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Heart Failure
Register for Updates
Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)
NCT05263076
Recruiting
Absolute Uterine Factor Infertility (AUFI) is due to congenital or surgical absence of a uterus or the presence of a nonfunctional uterus. Until 2014, the only option for women affected by Absolute Uterine Factor Infertility (AUFI) was adoption or surrogate motherhood. Uterine transplant is a new form of transplant to treat AUFI. The technique of uterus transplant was developed in Sweden with the transplantation of the uterus from a living donor to a woman affected by AUFI. Approximately 80 uter... Read More
Gender:
FEMALE
Ages:
Between 20 years and 65 years
Trial Updated:
05/05/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Mayer Rokitansky Kuster Hauser Syndrome, Absence of Uterus, Infertility of Uterine Origin
Register for Updates
CLEANer Aspiration for Pulmonary Embolism
NCT06189313
Recruiting
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Texas Heart Institute, Houston, Texas
Conditions: Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Register for Updates
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
NCT06445946
Recruiting
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factor... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of Texas Health Science Center, Houston, Texas
Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Register for Updates
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943
Recruiting
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
05/05/2025
Locations: Baylor College Of Medicine, Houston, Texas
Conditions: Lymphatic Malformations
Register for Updates
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
NCT06144151
Recruiting
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Neurotoxicity
Register for Updates
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
NCT06698822
Recruiting
To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cutaneous T-Cell Lymphoma
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Severe Aplastic Anemia
Register for Updates
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030
Recruiting
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: MD Anderson Cancer Center - Oncology, Houston, Texas
Conditions: Colorectal Cancer
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: Local Institution - 2127, Houston, Texas +1 locations
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates